Eric Venker
Chief Executive Officer at Immunovant Inc.
Sits on 1 board. Last updated September 27, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 1 year
- Director since
- 2025
1 year of board service in total across 1 board, counting each seat separately. Longest: Immunovant Inc., 1 year.
Chief executive roles
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 28, 2026 | Roivant Sciences Ltd. | Option exercise | +200,000 | $3.85 | $770,000 |
| Aug 28, 2026 | Roivant Sciences Ltd. | Open-market sale | โ166,182 | $35.63 | $5,921,065 |
| Aug 28, 2026 | Roivant Sciences Ltd. | Open-market sale | โ33,818 | $36.44 | $1,232,328 |
| Aug 20, 2026 | Roivant Sciences Ltd. | Shares withheld for tax | โ13,909 | $36.84 | $512,408 |
| Jul 27, 2026 | Roivant Sciences Ltd. | Option exercise | +200,000 | $3.85 | $770,000 |
| Jul 27, 2026 | Roivant Sciences Ltd. | Open-market sale | โ200,000 | $34.95 | $6,990,000 |
| Jul 2, 2026 | Immunovant Inc. | Open-market sale | โ3,092 | $38.48 | $118,980 |
| Jul 1, 2026 | Immunovant Inc. | Option exercise | +92,188 | $14.46 | $1,333,038 |
| Jul 1, 2026 | Immunovant Inc. | Sold back to the company | โ86,629 | $38.14 | $3,304,030 |
| Jun 24, 2026 | Roivant Sciences Ltd. | Option exercise | +200,000 | $3.85 | $770,000 |
| Jun 24, 2026 | Roivant Sciences Ltd. | Open-market sale | โ153,766 | $33.05 | $5,081,966 |
| Jun 24, 2026 | Roivant Sciences Ltd. | Open-market sale | โ46,234 | $33.51 | $1,549,301 |
| May 22, 2026 | Roivant Sciences Ltd. | Option exercise | +200,000 | $3.85 | $770,000 |
| May 22, 2026 | Roivant Sciences Ltd. | Open-market sale | โ200,000 | $30.27 | $6,054,000 |
| May 20, 2026 | Roivant Sciences Ltd. | Shares withheld for tax | โ34,483 | $32.41 | $1,117,594 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.